First line therapy | S/S + other N (%) | RT/RT + HO N (%) | P-value |
---|---|---|---|
Age (years) | |||
< 50 | 6 (1.6) | 2 (0.4) | < 0.001* |
≥ 50 and <60 | 107 (28) | 28 (5.3) | |
≥ 60 and <75 | 266 (69.6) | 401 (75.5) | |
≥ 75 and <80 | 2 (0.5) | 86 (16.2) | |
≥ 80 | 1 (0.3) | 14 (2.6) | |
Stage | |||
T1-T2 | 191 (50.1) | 360 (68.2) | < 0.001* |
T3 | 186 (48.8) | 156 (29.5) | |
T4 | 4 (1.1) | 12 (2.3) | |
Missing | 1 | 3 | |
Lymph nodes | |||
N0 | 322 (85.2) | 514 (98.3) | < 0.001* |
N1 | 56 (14.8) | 9 (1.7) | |
Missing | 4 | 8 | |
PSA (ng/ml) | |||
< 10 | 189 (56.4) | 180 (34.3) | < 0.001* |
10–20 | 101 (30.2) | 209 (39.9) | |
≥ 20 | 45 (13.4) | 135 (25.8) | |
Missing | 47 | 7 | |
Gleason Score | |||
3–6 | 79 (22.1) | 177 (35.9) | < 0.001* |
7 | 192 (53.6) | 171 (34.7) | |
8–10 | 87 (24.3) | 145 (29.4) | |
Missing | 24 | 38 | |
First metastatic event | |||
Bone-only | 30 (40.54) | 20 (32.26) | 0.158 |
Loco/LN-only | 28 (37.4) | 24 (38.71) | |
Visceral-only | 1 (1.35) | 6 (9.68) | |
Multiple site | 15 (20.27) | 12 (19.35) | |
Total (N) | 382 | 531 |